T2 Biosystems (NASDAQ:TTOO) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, Canaccord Genuity Group lifted their price target on shares of T2 Biosystems from $3.00 to $5.00 and gave the company a “hold” rating in a report on Tuesday, July 30th.

T2 Biosystems Price Performance

NASDAQ:TTOO traded down $0.02 during trading hours on Monday, hitting $0.49. 1,257,995 shares of the stock traded hands, compared to its average volume of 354,126. T2 Biosystems has a 1 year low of $0.42 and a 1 year high of $8.38. The stock has a 50 day moving average price of $1.27 and a 200 day moving average price of $3.37.

Institutional Investors Weigh In On T2 Biosystems

A hedge fund recently raised its stake in T2 Biosystems stock. Virtu Financial LLC grew its stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) by 29.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,096 shares of the medical equipment provider’s stock after purchasing an additional 3,018 shares during the quarter. Virtu Financial LLC owned approximately 0.24% of T2 Biosystems worth $39,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 23.18% of the company’s stock.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.